AustralieFrV1, Main, Exploration, bibRecord, 001040

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Identifieur interne : 001040 ( Main/Exploration ); précédent : 001039; suivant : 001041

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Auteurs : W-J Chng [Singapour] ; H. Goldschmidt [Allemagne] ; M A Dimopoulos [Grèce] ; P. Moreau [France] ; D. Joshua [Australie] ; A. Palumbo [Italie] ; T. Facon [France] ; H. Ludwig [Autriche] ; L. Pour [République tchèque] ; R. Niesvizky [États-Unis] ; A. Oriol [Espagne] ; L. Rosi Ol [Espagne] ; A. Suvorov [Russie] ; G. Gaidano [Italie] ; T. Pika [République tchèque] ; K. Weisel [Allemagne] ; V. Goranova-Marinova [Bulgarie] ; H H Gillenwater [États-Unis] ; N. Mohamed [États-Unis] ; S. Feng [États-Unis] ; S. Aggarwal [États-Unis] ; R. Hájek [République tchèque]

Source :

Leukemia [ 0887-6924 ] ; 2017.

RBID : PMC:5467042

Descripteurs français

KwdFr :
- Aberrations des chromosomes, Adulte, Analyse cytogénétique, Bortézomib (administration et posologie), Dexaméthasone (administration et posologie), Femelle, Grading des tumeurs, Humains, Induction de rémission, Marqueurs biologiques tumoraux, Myélome multiple (anatomopathologie), Myélome multiple (génétique), Myélome multiple (traitement médicamenteux), Mâle, Oligopeptides (administration et posologie), Pronostic, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Récidive tumorale locale (anatomopathologie), Récidive tumorale locale (génétique), Récidive tumorale locale (traitement médicamenteux), Résistance aux médicaments antinéoplasiques (), Résistance aux médicaments antinéoplasiques (génétique), Taux de survie, Thérapie de rattrapage, Études de suivi.
MESH :
- administration et posologie : Bortézomib, Dexaméthasone, Oligopeptides.
- anatomopathologie : Myélome multiple, Récidive tumorale locale.
- génétique : Myélome multiple, Récidive tumorale locale, Résistance aux médicaments antinéoplasiques.
- traitement médicamenteux : Myélome multiple, Récidive tumorale locale.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Aberrations des chromosomes, Adulte, Analyse cytogénétique, Femelle, Grading des tumeurs, Humains, Induction de rémission, Marqueurs biologiques tumoraux, Mâle, Pronostic, Résistance aux médicaments antinéoplasiques, Taux de survie, Thérapie de rattrapage, Études de suivi.

English descriptors

KwdEn :
- Adult, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biomarkers, Tumor, Bortezomib (administration & dosage), Chromosome Aberrations, Cytogenetic Analysis, Dexamethasone (administration & dosage), Drug Resistance, Neoplasm (drug effects), Drug Resistance, Neoplasm (genetics), Female, Follow-Up Studies, Humans, Male, Multiple Myeloma (drug therapy), Multiple Myeloma (genetics), Multiple Myeloma (pathology), Neoplasm Grading, Neoplasm Recurrence, Local (drug therapy), Neoplasm Recurrence, Local (genetics), Neoplasm Recurrence, Local (pathology), Oligopeptides (administration & dosage), Prognosis, Remission Induction, Salvage Therapy, Survival Rate.
MESH :
- chemical , administration & dosage : Bortezomib, Dexamethasone, Oligopeptides.
- chemical : Biomarkers, Tumor.
- drug effects : Drug Resistance, Neoplasm.
- drug therapy : Multiple Myeloma, Neoplasm Recurrence, Local.
- genetics : Drug Resistance, Neoplasm, Multiple Myeloma, Neoplasm Recurrence, Local.
- pathology : Multiple Myeloma, Neoplasm Recurrence, Local.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Chromosome Aberrations, Cytogenetic Analysis, Female, Follow-Up Studies, Humans, Male, Neoplasm Grading, Prognosis, Remission Induction, Salvage Therapy, Survival Rate.

Abstract

The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (MM). We conducted a preplanned subgroup analysis of ENDEAVOR to evaluate Kd vs Vd by cytogenetic risk. Of 785 patients with known cytogenetics, 210 (27%) had high-risk cytogenetics (Kd, n=97 (25%); Vd, n=113 (28%)) and 575 (73%) had standard-risk cytogenetics (Kd, n=284 (75%); Vd, n=291 (72%)). Median PFS in the high-risk group was 8.8 months for Kd vs 6.0 months for Vd (hazard ratio (HR), 0.65; 95% confidence interval (CI), 0.45–0.92; P=0.0075). Median PFS in the standard-risk group was not estimable for Kd vs 10.2 months for Vd (HR, 0.44; 95% CI, 0.33–0.58; P<0.0001). Overall response rates were 72.2% (Kd) vs 58.4% (Vd) in the high-risk group and 79.2% (Kd) vs 66.0% (Vd) in the standard-risk group. In the high-risk group, 15.5% (Kd) vs 4.4% (Vd) achieved a complete response (CR) or better. In the standard-risk group, 13.0% (Kd) vs 7.9% (Vd) achieved ⩾CR. This preplanned subgroup analysis found that Kd was superior to Vd in relapsed or refractory MM, regardless of cytogenetic risk.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467042

DOI: 10.1038/leu.2016.390
PubMed: 28025582
PubMed Central: 5467042

Affiliations:

Allemagne, Australie, Autriche, Bulgarie, Espagne, France, Grèce, Italie, Russie, République tchèque, Singapour, États-Unis

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR</title>
<author><name sortKey="Chng, W J" sort="Chng, W J" uniqKey="Chng W" first="W-J" last="Chng">W-J Chng</name>
<affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Department of Haematology-Oncology, National University Cancer Institute, National University Health System</institution>
, Singapore,<country>Singapore</country>
</nlm:aff>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Department of Haematology-Oncology, Cancer Science Institute of Singapore, National University of Singapore</institution>
, Singapore,<country>Singapore</country>
</nlm:aff>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Goldschmidt, H" sort="Goldschmidt, H" uniqKey="Goldschmidt H" first="H" last="Goldschmidt">H. Goldschmidt</name>
<affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Department of Internal Medicine, Heidelberg Medical University</institution>
, Heidelberg,<country>Germany</country>
</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dimopoulos, M A" sort="Dimopoulos, M A" uniqKey="Dimopoulos M" first="M A" last="Dimopoulos">M A Dimopoulos</name>
<affiliation wicri:level="1"><nlm:aff id="aff4"><institution>School of Medicine, National and Kapodistrian University of Athens</institution>
, Athens,<country>Greece</country>
</nlm:aff>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moreau, P" sort="Moreau, P" uniqKey="Moreau P" first="P" last="Moreau">P. Moreau</name>
<affiliation wicri:level="1"><nlm:aff id="aff5"><institution>Department of Haematology, University of Nantes</institution>
, Nantes,<country>France</country>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Joshua, D" sort="Joshua, D" uniqKey="Joshua D" first="D" last="Joshua">D. Joshua</name>
<affiliation wicri:level="1"><nlm:aff id="aff6"><institution>Department of Haematology, Royal Prince Alfred Hospital</institution>
, Camperdown, New South Wales,<country>Australia</country>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Palumbo, A" sort="Palumbo, A" uniqKey="Palumbo A" first="A" last="Palumbo">A. Palumbo</name>
<affiliation wicri:level="1"><nlm:aff id="aff7"><institution>Department of Oncology, University of Torino</institution>
, Torino,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Facon, T" sort="Facon, T" uniqKey="Facon T" first="T" last="Facon">T. Facon</name>
<affiliation wicri:level="1"><nlm:aff id="aff8"><institution>Department of Haematology, CHRU Lille Hôpital Claude Huriez</institution>
, Lille,<country>France</country>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ludwig, H" sort="Ludwig, H" uniqKey="Ludwig H" first="H" last="Ludwig">H. Ludwig</name>
<affiliation wicri:level="1"><nlm:aff id="aff9"><institution>Department of Medicine, Wilhelminen Cancer Research Institute, Wilhelminenspital</institution>
, Vienna,<country>Austria</country>
</nlm:aff>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pour, L" sort="Pour, L" uniqKey="Pour L" first="L" last="Pour">L. Pour</name>
<affiliation wicri:level="1"><nlm:aff id="aff10"><institution>Myeloma Group, University Hospital Brno</institution>
, Brno,<country>Czech Republic</country>
</nlm:aff>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Niesvizky, R" sort="Niesvizky, R" uniqKey="Niesvizky R" first="R" last="Niesvizky">R. Niesvizky</name>
<affiliation wicri:level="1"><nlm:aff id="aff11"><institution>Multiple Myeloma Center, Weill Cornell Medical College, New York Presbyterian Hospital</institution>
, New York, NY,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Oriol, A" sort="Oriol, A" uniqKey="Oriol A" first="A" last="Oriol">A. Oriol</name>
<affiliation wicri:level="1"><nlm:aff id="aff12"><institution>Department of Clinical Haematology, Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol</institution>
, Barcelona,<country>Spain</country>
</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rosi Ol, L" sort="Rosi Ol, L" uniqKey="Rosi Ol L" first="L" last="Rosi Ol">L. Rosi Ol</name>
<affiliation wicri:level="1"><nlm:aff id="aff13"><institution>Department of Haematology, Hospital Clínic de Barcelona</institution>
, Barcelona,<country>Spain</country>
</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Suvorov, A" sort="Suvorov, A" uniqKey="Suvorov A" first="A" last="Suvorov">A. Suvorov</name>
<affiliation wicri:level="1"><nlm:aff id="aff14"><institution>Hematological Department, First Republican Clinical Hospital of Udmurtia</institution>
, Izhevsk,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gaidano, G" sort="Gaidano, G" uniqKey="Gaidano G" first="G" last="Gaidano">G. Gaidano</name>
<affiliation wicri:level="1"><nlm:aff id="aff15"><institution>Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont</institution>
, Novara,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pika, T" sort="Pika, T" uniqKey="Pika T" first="T" last="Pika">T. Pika</name>
<affiliation wicri:level="1"><nlm:aff id="aff16"><institution>Department of Hematooncology, University Hospital Olomouc</institution>
, Olomouc,<country>Czech Republic</country>
</nlm:aff>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Weisel, K" sort="Weisel, K" uniqKey="Weisel K" first="K" last="Weisel">K. Weisel</name>
<affiliation wicri:level="1"><nlm:aff id="aff17"><institution>Myeloma Clinic, Universitatsklinikum Tubingen</institution>
, Tubingen,<country>Germany</country>
</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Goranova Marinova, V" sort="Goranova Marinova, V" uniqKey="Goranova Marinova V" first="V" last="Goranova-Marinova">V. Goranova-Marinova</name>
<affiliation wicri:level="1"><nlm:aff id="aff18"><institution>Haematooncology Clinic, University Multiprofile Hospital for Active Treatment ‘Sveti Georgi' and Medical University</institution>
, Plovdiv,<country>Bulgaria</country>
</nlm:aff>
<country xml:lang="fr">Bulgarie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gillenwater, H H" sort="Gillenwater, H H" uniqKey="Gillenwater H" first="H H" last="Gillenwater">H H Gillenwater</name>
<affiliation wicri:level="1"><nlm:aff id="aff19"><institution>Onyx Pharmaceuticals, Inc., an Amgen subsidiary</institution>
, South San Francisco, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mohamed, N" sort="Mohamed, N" uniqKey="Mohamed N" first="N" last="Mohamed">N. Mohamed</name>
<affiliation wicri:level="1"><nlm:aff id="aff19"><institution>Onyx Pharmaceuticals, Inc., an Amgen subsidiary</institution>
, South San Francisco, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Feng, S" sort="Feng, S" uniqKey="Feng S" first="S" last="Feng">S. Feng</name>
<affiliation wicri:level="1"><nlm:aff id="aff19"><institution>Onyx Pharmaceuticals, Inc., an Amgen subsidiary</institution>
, South San Francisco, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Aggarwal, S" sort="Aggarwal, S" uniqKey="Aggarwal S" first="S" last="Aggarwal">S. Aggarwal</name>
<affiliation wicri:level="1"><nlm:aff id="aff19"><institution>Onyx Pharmaceuticals, Inc., an Amgen subsidiary</institution>
, South San Francisco, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hajek, R" sort="Hajek, R" uniqKey="Hajek R" first="R" last="Hájek">R. Hájek</name>
<affiliation wicri:level="1"><nlm:aff id="aff20"><institution>Department of Haematooncology, University Hospital Ostrava, Faculty of Medicine, University of Ostrava</institution>
, Ostrava,<country>Czech Republic</country>
</nlm:aff>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">28025582</idno>
<idno type="pmc">5467042</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467042</idno>
<idno type="RBID">PMC:5467042</idno>
<idno type="doi">10.1038/leu.2016.390</idno>
<date when="2017">2017</date>
<idno type="wicri:Area/Pmc/Corpus">000729</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000729</idno>
<idno type="wicri:Area/Pmc/Curation">000728</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000728</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000402</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000402</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000A78</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A78</idno>
<idno type="wicri:Area/PubMed/Curation">000A75</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A75</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000A75</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A75</idno>
<idno type="wicri:Area/Ncbi/Merge">004093</idno>
<idno type="wicri:Area/Ncbi/Curation">004093</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004093</idno>
<idno type="wicri:doubleKey">0887-6924:2017:Chng W:carfilzomib:dexamethasone:vs</idno>
<idno type="wicri:Area/Main/Merge">001035</idno>
<idno type="wicri:Area/Main/Curation">001040</idno>
<idno type="wicri:Area/Main/Exploration">001040</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR</title>
<author><name sortKey="Chng, W J" sort="Chng, W J" uniqKey="Chng W" first="W-J" last="Chng">W-J Chng</name>
<affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Department of Haematology-Oncology, National University Cancer Institute, National University Health System</institution>
, Singapore,<country>Singapore</country>
</nlm:aff>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Department of Haematology-Oncology, Cancer Science Institute of Singapore, National University of Singapore</institution>
, Singapore,<country>Singapore</country>
</nlm:aff>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Goldschmidt, H" sort="Goldschmidt, H" uniqKey="Goldschmidt H" first="H" last="Goldschmidt">H. Goldschmidt</name>
<affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Department of Internal Medicine, Heidelberg Medical University</institution>
, Heidelberg,<country>Germany</country>
</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dimopoulos, M A" sort="Dimopoulos, M A" uniqKey="Dimopoulos M" first="M A" last="Dimopoulos">M A Dimopoulos</name>
<affiliation wicri:level="1"><nlm:aff id="aff4"><institution>School of Medicine, National and Kapodistrian University of Athens</institution>
, Athens,<country>Greece</country>
</nlm:aff>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moreau, P" sort="Moreau, P" uniqKey="Moreau P" first="P" last="Moreau">P. Moreau</name>
<affiliation wicri:level="1"><nlm:aff id="aff5"><institution>Department of Haematology, University of Nantes</institution>
, Nantes,<country>France</country>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Joshua, D" sort="Joshua, D" uniqKey="Joshua D" first="D" last="Joshua">D. Joshua</name>
<affiliation wicri:level="1"><nlm:aff id="aff6"><institution>Department of Haematology, Royal Prince Alfred Hospital</institution>
, Camperdown, New South Wales,<country>Australia</country>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Palumbo, A" sort="Palumbo, A" uniqKey="Palumbo A" first="A" last="Palumbo">A. Palumbo</name>
<affiliation wicri:level="1"><nlm:aff id="aff7"><institution>Department of Oncology, University of Torino</institution>
, Torino,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Facon, T" sort="Facon, T" uniqKey="Facon T" first="T" last="Facon">T. Facon</name>
<affiliation wicri:level="1"><nlm:aff id="aff8"><institution>Department of Haematology, CHRU Lille Hôpital Claude Huriez</institution>
, Lille,<country>France</country>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ludwig, H" sort="Ludwig, H" uniqKey="Ludwig H" first="H" last="Ludwig">H. Ludwig</name>
<affiliation wicri:level="1"><nlm:aff id="aff9"><institution>Department of Medicine, Wilhelminen Cancer Research Institute, Wilhelminenspital</institution>
, Vienna,<country>Austria</country>
</nlm:aff>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pour, L" sort="Pour, L" uniqKey="Pour L" first="L" last="Pour">L. Pour</name>
<affiliation wicri:level="1"><nlm:aff id="aff10"><institution>Myeloma Group, University Hospital Brno</institution>
, Brno,<country>Czech Republic</country>
</nlm:aff>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Niesvizky, R" sort="Niesvizky, R" uniqKey="Niesvizky R" first="R" last="Niesvizky">R. Niesvizky</name>
<affiliation wicri:level="1"><nlm:aff id="aff11"><institution>Multiple Myeloma Center, Weill Cornell Medical College, New York Presbyterian Hospital</institution>
, New York, NY,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Oriol, A" sort="Oriol, A" uniqKey="Oriol A" first="A" last="Oriol">A. Oriol</name>
<affiliation wicri:level="1"><nlm:aff id="aff12"><institution>Department of Clinical Haematology, Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol</institution>
, Barcelona,<country>Spain</country>
</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rosi Ol, L" sort="Rosi Ol, L" uniqKey="Rosi Ol L" first="L" last="Rosi Ol">L. Rosi Ol</name>
<affiliation wicri:level="1"><nlm:aff id="aff13"><institution>Department of Haematology, Hospital Clínic de Barcelona</institution>
, Barcelona,<country>Spain</country>
</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Suvorov, A" sort="Suvorov, A" uniqKey="Suvorov A" first="A" last="Suvorov">A. Suvorov</name>
<affiliation wicri:level="1"><nlm:aff id="aff14"><institution>Hematological Department, First Republican Clinical Hospital of Udmurtia</institution>
, Izhevsk,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gaidano, G" sort="Gaidano, G" uniqKey="Gaidano G" first="G" last="Gaidano">G. Gaidano</name>
<affiliation wicri:level="1"><nlm:aff id="aff15"><institution>Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont</institution>
, Novara,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pika, T" sort="Pika, T" uniqKey="Pika T" first="T" last="Pika">T. Pika</name>
<affiliation wicri:level="1"><nlm:aff id="aff16"><institution>Department of Hematooncology, University Hospital Olomouc</institution>
, Olomouc,<country>Czech Republic</country>
</nlm:aff>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Weisel, K" sort="Weisel, K" uniqKey="Weisel K" first="K" last="Weisel">K. Weisel</name>
<affiliation wicri:level="1"><nlm:aff id="aff17"><institution>Myeloma Clinic, Universitatsklinikum Tubingen</institution>
, Tubingen,<country>Germany</country>
</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Goranova Marinova, V" sort="Goranova Marinova, V" uniqKey="Goranova Marinova V" first="V" last="Goranova-Marinova">V. Goranova-Marinova</name>
<affiliation wicri:level="1"><nlm:aff id="aff18"><institution>Haematooncology Clinic, University Multiprofile Hospital for Active Treatment ‘Sveti Georgi' and Medical University</institution>
, Plovdiv,<country>Bulgaria</country>
</nlm:aff>
<country xml:lang="fr">Bulgarie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gillenwater, H H" sort="Gillenwater, H H" uniqKey="Gillenwater H" first="H H" last="Gillenwater">H H Gillenwater</name>
<affiliation wicri:level="1"><nlm:aff id="aff19"><institution>Onyx Pharmaceuticals, Inc., an Amgen subsidiary</institution>
, South San Francisco, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mohamed, N" sort="Mohamed, N" uniqKey="Mohamed N" first="N" last="Mohamed">N. Mohamed</name>
<affiliation wicri:level="1"><nlm:aff id="aff19"><institution>Onyx Pharmaceuticals, Inc., an Amgen subsidiary</institution>
, South San Francisco, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Feng, S" sort="Feng, S" uniqKey="Feng S" first="S" last="Feng">S. Feng</name>
<affiliation wicri:level="1"><nlm:aff id="aff19"><institution>Onyx Pharmaceuticals, Inc., an Amgen subsidiary</institution>
, South San Francisco, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Aggarwal, S" sort="Aggarwal, S" uniqKey="Aggarwal S" first="S" last="Aggarwal">S. Aggarwal</name>
<affiliation wicri:level="1"><nlm:aff id="aff19"><institution>Onyx Pharmaceuticals, Inc., an Amgen subsidiary</institution>
, South San Francisco, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hajek, R" sort="Hajek, R" uniqKey="Hajek R" first="R" last="Hájek">R. Hájek</name>
<affiliation wicri:level="1"><nlm:aff id="aff20"><institution>Department of Haematooncology, University Hospital Ostrava, Faculty of Medicine, University of Ostrava</institution>
, Ostrava,<country>Czech Republic</country>
</nlm:aff>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Leukemia</title>
<idno type="ISSN">0887-6924</idno>
<idno type="eISSN">1476-5551</idno>
<imprint><date when="2017">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Biomarkers, Tumor</term>
<term>Bortezomib (administration & dosage)</term>
<term>Chromosome Aberrations</term>
<term>Cytogenetic Analysis</term>
<term>Dexamethasone (administration & dosage)</term>
<term>Drug Resistance, Neoplasm (drug effects)</term>
<term>Drug Resistance, Neoplasm (genetics)</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Multiple Myeloma (drug therapy)</term>
<term>Multiple Myeloma (genetics)</term>
<term>Multiple Myeloma (pathology)</term>
<term>Neoplasm Grading</term>
<term>Neoplasm Recurrence, Local (drug therapy)</term>
<term>Neoplasm Recurrence, Local (genetics)</term>
<term>Neoplasm Recurrence, Local (pathology)</term>
<term>Oligopeptides (administration & dosage)</term>
<term>Prognosis</term>
<term>Remission Induction</term>
<term>Salvage Therapy</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Aberrations des chromosomes</term>
<term>Adulte</term>
<term>Analyse cytogénétique</term>
<term>Bortézomib (administration et posologie)</term>
<term>Dexaméthasone (administration et posologie)</term>
<term>Femelle</term>
<term>Grading des tumeurs</term>
<term>Humains</term>
<term>Induction de rémission</term>
<term>Marqueurs biologiques tumoraux</term>
<term>Myélome multiple (anatomopathologie)</term>
<term>Myélome multiple (génétique)</term>
<term>Myélome multiple (traitement médicamenteux)</term>
<term>Mâle</term>
<term>Oligopeptides (administration et posologie)</term>
<term>Pronostic</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Récidive tumorale locale (anatomopathologie)</term>
<term>Récidive tumorale locale (génétique)</term>
<term>Récidive tumorale locale (traitement médicamenteux)</term>
<term>Résistance aux médicaments antinéoplasiques ()</term>
<term>Résistance aux médicaments antinéoplasiques (génétique)</term>
<term>Taux de survie</term>
<term>Thérapie de rattrapage</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bortezomib</term>
<term>Dexamethasone</term>
<term>Oligopeptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Biomarkers, Tumor</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Bortézomib</term>
<term>Dexaméthasone</term>
<term>Oligopeptides</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Myélome multiple</term>
<term>Récidive tumorale locale</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Drug Resistance, Neoplasm</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple Myeloma</term>
<term>Neoplasm Recurrence, Local</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Drug Resistance, Neoplasm</term>
<term>Multiple Myeloma</term>
<term>Neoplasm Recurrence, Local</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Myélome multiple</term>
<term>Récidive tumorale locale</term>
<term>Résistance aux médicaments antinéoplasiques</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Multiple Myeloma</term>
<term>Neoplasm Recurrence, Local</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Myélome multiple</term>
<term>Récidive tumorale locale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Chromosome Aberrations</term>
<term>Cytogenetic Analysis</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Neoplasm Grading</term>
<term>Prognosis</term>
<term>Remission Induction</term>
<term>Salvage Therapy</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Aberrations des chromosomes</term>
<term>Adulte</term>
<term>Analyse cytogénétique</term>
<term>Femelle</term>
<term>Grading des tumeurs</term>
<term>Humains</term>
<term>Induction de rémission</term>
<term>Marqueurs biologiques tumoraux</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Taux de survie</term>
<term>Thérapie de rattrapage</term>
<term>Études de suivi</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (MM). We conducted a preplanned subgroup analysis of ENDEAVOR to evaluate Kd vs Vd by cytogenetic risk. Of 785 patients with known cytogenetics, 210 (27%) had high-risk cytogenetics (Kd, <italic>n</italic>
=97 (25%); Vd, <italic>n</italic>
=113 (28%)) and 575 (73%) had standard-risk cytogenetics (Kd, <italic>n</italic>
=284 (75%); Vd, <italic>n</italic>
=291 (72%)). Median PFS in the high-risk group was 8.8 months for Kd vs 6.0 months for Vd (hazard ratio (HR), 0.65; 95% confidence interval (CI), 0.45–0.92; <italic>P</italic>
=0.0075). Median PFS in the standard-risk group was not estimable for Kd vs 10.2 months for Vd (HR, 0.44; 95% CI, 0.33–0.58; <italic>P</italic>
<0.0001). Overall response rates were 72.2% (Kd) vs 58.4% (Vd) in the high-risk group and 79.2% (Kd) vs 66.0% (Vd) in the standard-risk group. In the high-risk group, 15.5% (Kd) vs 4.4% (Vd) achieved a complete response (CR) or better. In the standard-risk group, 13.0% (Kd) vs 7.9% (Vd) achieved ⩾CR. This preplanned subgroup analysis found that Kd was superior to Vd in relapsed or refractory MM, regardless of cytogenetic risk.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Autriche</li>
<li>Bulgarie</li>
<li>Espagne</li>
<li>France</li>
<li>Grèce</li>
<li>Italie</li>
<li>Russie</li>
<li>République tchèque</li>
<li>Singapour</li>
<li>États-Unis</li>
</country>
</list>
<tree><country name="Singapour"><noRegion><name sortKey="Chng, W J" sort="Chng, W J" uniqKey="Chng W" first="W-J" last="Chng">W-J Chng</name>
</noRegion>
<name sortKey="Chng, W J" sort="Chng, W J" uniqKey="Chng W" first="W-J" last="Chng">W-J Chng</name>
</country>
<country name="Allemagne"><noRegion><name sortKey="Goldschmidt, H" sort="Goldschmidt, H" uniqKey="Goldschmidt H" first="H" last="Goldschmidt">H. Goldschmidt</name>
</noRegion>
<name sortKey="Weisel, K" sort="Weisel, K" uniqKey="Weisel K" first="K" last="Weisel">K. Weisel</name>
</country>
<country name="Grèce"><noRegion><name sortKey="Dimopoulos, M A" sort="Dimopoulos, M A" uniqKey="Dimopoulos M" first="M A" last="Dimopoulos">M A Dimopoulos</name>
</noRegion>
</country>
<country name="France"><noRegion><name sortKey="Moreau, P" sort="Moreau, P" uniqKey="Moreau P" first="P" last="Moreau">P. Moreau</name>
</noRegion>
<name sortKey="Facon, T" sort="Facon, T" uniqKey="Facon T" first="T" last="Facon">T. Facon</name>
</country>
<country name="Australie"><noRegion><name sortKey="Joshua, D" sort="Joshua, D" uniqKey="Joshua D" first="D" last="Joshua">D. Joshua</name>
</noRegion>
</country>
<country name="Italie"><noRegion><name sortKey="Palumbo, A" sort="Palumbo, A" uniqKey="Palumbo A" first="A" last="Palumbo">A. Palumbo</name>
</noRegion>
<name sortKey="Gaidano, G" sort="Gaidano, G" uniqKey="Gaidano G" first="G" last="Gaidano">G. Gaidano</name>
</country>
<country name="Autriche"><noRegion><name sortKey="Ludwig, H" sort="Ludwig, H" uniqKey="Ludwig H" first="H" last="Ludwig">H. Ludwig</name>
</noRegion>
</country>
<country name="République tchèque"><noRegion><name sortKey="Pour, L" sort="Pour, L" uniqKey="Pour L" first="L" last="Pour">L. Pour</name>
</noRegion>
<name sortKey="Hajek, R" sort="Hajek, R" uniqKey="Hajek R" first="R" last="Hájek">R. Hájek</name>
<name sortKey="Pika, T" sort="Pika, T" uniqKey="Pika T" first="T" last="Pika">T. Pika</name>
</country>
<country name="États-Unis"><noRegion><name sortKey="Niesvizky, R" sort="Niesvizky, R" uniqKey="Niesvizky R" first="R" last="Niesvizky">R. Niesvizky</name>
</noRegion>
<name sortKey="Aggarwal, S" sort="Aggarwal, S" uniqKey="Aggarwal S" first="S" last="Aggarwal">S. Aggarwal</name>
<name sortKey="Feng, S" sort="Feng, S" uniqKey="Feng S" first="S" last="Feng">S. Feng</name>
<name sortKey="Gillenwater, H H" sort="Gillenwater, H H" uniqKey="Gillenwater H" first="H H" last="Gillenwater">H H Gillenwater</name>
<name sortKey="Mohamed, N" sort="Mohamed, N" uniqKey="Mohamed N" first="N" last="Mohamed">N. Mohamed</name>
</country>
<country name="Espagne"><noRegion><name sortKey="Oriol, A" sort="Oriol, A" uniqKey="Oriol A" first="A" last="Oriol">A. Oriol</name>
</noRegion>
<name sortKey="Rosi Ol, L" sort="Rosi Ol, L" uniqKey="Rosi Ol L" first="L" last="Rosi Ol">L. Rosi Ol</name>
</country>
<country name="Russie"><noRegion><name sortKey="Suvorov, A" sort="Suvorov, A" uniqKey="Suvorov A" first="A" last="Suvorov">A. Suvorov</name>
</noRegion>
</country>
<country name="Bulgarie"><noRegion><name sortKey="Goranova Marinova, V" sort="Goranova Marinova, V" uniqKey="Goranova Marinova V" first="V" last="Goranova-Marinova">V. Goranova-Marinova</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001040 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001040 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:5467042
   |texte=   Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28025582" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.